Novo Nordisk shares jump after US approves Wegovy for liver disease - Latest news from Azerbaijan
Latest news from Azerbaijanarrow_outwardStock Movers: SHCO, DAY, Novo Nordisk - Bloomberg.com
Bloomberg.comarrow_outwardNovo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease
CNBCarrow_outwardFDA Approves Novo Nordisk’s Wegovy for Liver Disease
The Wall Street Journalarrow_outwardWegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
PR Newswirearrow_outwardIs Novo Nordisk's 70% Stock Plunge a Golden Opportunity for Value Investors? - AInvest
AInvestarrow_outwardNovo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It. - Barron's
Barron'sarrow_outwardWhat's Going On With Novo Nordisk Stock Monday? - Novo Nordisk (NYSE:NVO) - Benzinga
Benzingaarrow_outwardWhy Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Today - MSN
MSNarrow_outwardWhy Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Today - Stocktwits
Stocktwitsarrow_outwardTrending tickers: Novo Nordisk, Palo Alto Networks, Walmart, Soho House and Nio - uk.finance.yahoo.com
Uk.finance.yahoo.comarrow_outwardShares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment - Reuters
Reutersarrow_outwardNovo Nordisk shares are rising. The FDA approves another use for Wegovy. - MarketWatch
MarketWatcharrow_outwardShares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment By Reuters - Investing.com
Investing.comarrow_outwardNovo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease - TipRanks
TipRanksarrow_outwardNovo Nordisk Secures FDA Approval Amplifying Market Prospects - StocksToTrade
StocksToTradearrow_outward1 Stock Down 40% This Year to Buy and Hold - The Globe and Mail
The Globe and Mailarrow_outward1 Stock Down 40% This Year to Buy and Hold - The Motley Fool
The Motley Foolarrow_outwardEli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead - Seeking Alpha
Seeking Alphaarrow_outwardBreakthrough: First-Ever Treatment for MASH - Novo Nordisk's Wegovy Shows 63% Success in Liver Disease - Stock Titan
Stock Titanarrow_outwardWhy Novo Nordisk Flew Almost 3% Higher on Friday - Yahoo Finance
Yahoo Financearrow_outwardIs Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive r - The Economic Times
The Economic Timesarrow_outwardNovo Nordisk Stock (NVO) Opinions on Q2 Earnings Miss and Guidance Cut - Quiver Quantitative
Quiver Quantitativearrow_outwardNovo Nordisk Stock: Buy or Sell? - Nasdaq
Nasdaqarrow_outwardEli Lilly and Novo Nordisk whipsawed by Wall Street's ever-rising hopes for weight loss drugs - Quartz
Quartzarrow_outwardNovo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic - Investor's Business Daily
Investor's Business Dailyarrow_outwardNovo Nordisk keeps growing, fuelling hopes of a stock rebound - Euronews.com
Euronews.comarrow_outwardNovo Nordisk Stock Sinks—But Is a Bottom Finally In? - MarketBeat
MarketBeatarrow_outwardWatch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop - Investopedia
Investopediaarrow_outwardOzempic Maker’s Stock Plunges 20% After Profit Warning - The New York Times
The New York Timesarrow_outwardNVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar? - Fast Company
Fast Companyarrow_outwardNovo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook - CBS News
CBS Newsarrow_outwardHere’s What Happened The Last Time Novo Nordisk Stock Was This Oversold - Barchart.com
Barchart.comarrow_outwardNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock? - Zacks Investment Research
Zacks Investment Researcharrow_outward
Novo Nordisk Stock close
- 2025-08-18 19:20 event
- 34 sourceslanguage
- 100+ ads_click
- 2 weeks ago schedule